Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EquasensFRA:PHF 98 ROC (Joel Greenblatt) % is 219.66% as of Dec. 2025, which is 10% above its 10-year median of 200.54. GuruFocus rates FRA:PHF with a GF Score™ of 98/100 and a GF Value™ of €90.29. The stock has 3 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Equasens ranks better than 92.84% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Equasens's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 219.66%.
The historical rank and industry rank for Equasens's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:PHF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 153.53 Med: 200.54 Max: 612.39
Current: 179.45
During the past 13 years, Equasens's highest ROC (Joel Greenblatt) % was 612.39%. The lowest was 153.53%. And the median was 200.54%.
FRA:PHF's ROC (Joel Greenblatt) % is ranked better than 92.84% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 12.43
vs FRA:PHF: 179.45
Equasens's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Equasens's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHF vs VEEV, BTSG, TEM: ROC (Joel Greenblatt) % Comparison
For the Health Information Services subindustry, Equasens's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Equasens's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 219.66% mean?
Equasens (FRA:PHF) has a ROC (Joel Greenblatt) % of 219.66% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Equasens and its competitors. This is 10% above median its historical median of 200.54. Over the past decade, Equasens' ROC (Joel Greenblatt) % has ranged from 153.53 to 612.39. According to the industry distribution chart, Equasens ranks #48 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 7.2%.
Is Equasens' ROC (Joel Greenblatt) % too high?
Equasens' current ROC (Joel Greenblatt) % of 219.66% is 10% above median its 10-year median of 200.54. Over the past 10 years, this metric has ranged from a low of 153.53 to a high of 612.39. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.43. Equasens' value of 219.66% is 1667.2% above this industry median. Based on the distribution chart, Equasens ranks #48 out of 670 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' ROC (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #48 out of 670 companies for ROC (Joel Greenblatt) %. This places Equasens in the top 7% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 12.43. Equasens' value of 219.66% is 1667.2% above this benchmark. Historically, Equasens' own ROC (Joel Greenblatt) % has ranged from 153.53 to 612.39 over the past decade. While the company's 10-year median is 200.54 vs. the industry median of 12.43, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.43, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current ROC (Joel Greenblatt) % of 219.66% is 1667.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current ROC (Joel Greenblatt) % is 219.66%, which is 10% above median its own 10-year median of 200.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current ROC (Joel Greenblatt) % of 219.66%. The stock's GF Value™ is €90.29, compared to a current price of €52.77 — trading 41.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 219.66%, which is 10% above median its 10-year median of 200.54 and 1667.2% above the Healthcare Providers & Services industry median of 12.43. Equasens' overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Equasens (FRA:PHF), the current ROC (Joel Greenblatt) % is 219.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 41.6% below its estimated GF Value™ of €90.29.
Key valuation signals for FRA:PHF:
ROC (Joel Greenblatt) %: 219.66% (10% above median its 10-year median of 200.54)
GF Value™: €90.29 vs. price of €52.77 (41.6% below fair value)
Industry Position: 1667.2% above the Healthcare Providers & Services median (#48 of 670)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
98GF Score
Get the complete analysis for FRA:PHF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
